Evidence map›Paper›PMID 41377997›Full record

ArticleResearch square2025

Targeting central immune signaling enhances the effects of methylphenidate in alleviating apathy-like behavior in 5xFAD mice.

Raisa Monteiro, Jeffrey T Dunn, Guadalupe Rodriguez, Daniel W Fisher, Hongxin Dong

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Raisa MonteiroNorthwestern University Feinberg School of Medicine.
Jeffrey T DunnNorthwestern University Feinberg School of Medicine.
Guadalupe RodriguezNorthwestern University Feinberg School of Medicine.
Daniel W FisherUniversity of Washington School of Medicine.
Hongxin DongNorthwestern University Feinberg School of Medicine.

Funding

Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's DiseaseT32AG052354 · NIA · UNIVERSITY OF WASHINGTON · PI Brian C. Kraemer, ELAINE R. PESKIND · 2016 to 2026
$6.7M
Molecular Mechanisms Underlying Behavioral and Psychological Symptoms in Alzheimers DiseaseR01AG062249 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI DONG, HONGXIN, WILSON, ROBERT S · 2018 to 2022
$3.5M
Epigenetic Regulation in Aging and Alzheimer's DiseaseR01AG079989 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Hongxin Dong · 2023 to 2026
$2.6M
NIA NIH HHS R01 AG062249NIA NIH HHS R01 AG079989NIA NIH HHS T32 AG052354
6 · The paper itself

Abstract

Alzheimer's disease (AD) is frequently accompanied by neuropsychiatric symptoms (NPS), among which apathy, one of the most prevalent and burdensome, accelerates cognitive decline and disease progression, yet its molecular underpinnings remain unclear. Our previous RNA-sequencing of AD subjects revealed abnormal immune gene expression uniquely associated with apathy. In this study, we investigated whether these changes are also linked to apathy-like behavior in 5xFAD mice, and whether administration of C3a receptor antagonist SB290157, alone or with methylphenidate, modifies these behaviors. We first validated the expression of apathy-related immune hub genes identified in human AD in the prefrontal cortex (PFC) of 16-month-old 5xFAD mice using RT-qPCR. Separate cohorts of similarly aged 5xFAD and WT mice then received SB290157 and/or methylphenidate for two weeks. Results indicate that increased immune-related genes, including

Indexed as

Alzheimer’s DiseaseApathyC3ar antagonistComplement PathwayImmune SystemMethylphenidate

Identifiers

PMID41377997
PMCPMC12687839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.